Background: Glioma is an exceedingly diverse brain tumor whose pathogenesis is complex and not yet fully understood. In recent years, as bioinformatics and molecular biology technologies have advanced, scholars have increasingly come to understand the tenuous connection and causal relationship between gene regulatory networks and the development and progression of glioma. However, the current state of research in this area remains ambiguous.
Materials and methods: This study analyzed protein data from the deCODE database and gene expression data of glioma patients from the TCGA and GEO databases to identify key genes associated with glioma. We then employed a range of techniques to investigate the mechanism by which crucial genes contribute to the development and occurrence of glioma. These methods were single-cell analysis, sensitivity analysis, heterogeneity testing, co-localization analysis, signaling pathway analysis, regulatory network analysis, and building an miRNA network. These investigations aimed to provide evidence for future clinical trials involving adjuvant chemotherapy drugs.
Results: A total of nine crucial genes (RAB 13, SCARA5, S100A12, DNAJB9, GSTZ 1, LY 9, ASPN, PLXDC1, and TREM 1) exhibited a strong correlation with the occurrence, and LY9, ASPN, PLXDC1, and TREM1 showed a reduced risk of glioma, while RAB 13, SCARA5, S100A12, DNAJB9, and GSTZ1 demonstrated significant regulatory functions in glioma. However, these analyses did not provide a comprehensive understanding of the mgliomas. The use of drug sensitivity analysis enabled the creation of personalized treatment plans, which were strongly linked to the development and appearance of gliomas. The utilization of drug sensitivity analysis enabled the implementation of personalized treatment plans.
Conclusion: By employing a range of bioinformatics and molecular biology techniques, this research has extensively investigated the mechanism of action of genes associated with glioma. This research has established a novel theoretical foundation for the treatment of glioma and conceived individualized and targeted therapies.